A 3-year study of prevention of postmenopausal bone loss: Conjugated equine estrogens plus medroxyprogesterone acetate versus tibolone

Climacteric

Volumn 1, Issue 3, 1998, Pages 202-210

  Thiebaud D ^a   Bigler, J M ^a   Renteria, S ^a   Pache, T ^a   Welti, H J ^a   Landry, M ^a   Burckhardt, P ^a  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

Bone mineral density; Conjugated equine estrogens; Medroxyprogesterone acetate; Osteoporosis; Tibolone

Indexed keywords

ALKALINE PHOSPHATASE; CALCIUM; CONJUGATED ESTROGEN; CREATININE; HYDROXYPROLINE; MEDROXYPROGESTERONE ACETATE; OSTEOCALCIN; PREGNANE DERIVATIVE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C; TIBOLONE;

ANIMAL; ARTICLE; BLOOD; BONE DENSITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; ESTROGEN THERAPY; FEMALE; FEMUR; HORSE; HUMAN; LUMBAR VERTEBRA; POSTMENOPAUSE OSTEOPOROSIS; RADIODENSITOMETRY; RANDOMIZED CONTROLLED TRIAL; URINE;

ALKALINE PHOSPHATASE; ANIMALS; BONE DENSITY; CALCIUM; CREATININE; DENSITOMETRY, X-RAY; ESTROGEN RECEPTOR MODULATORS; ESTROGEN REPLACEMENT THERAPY; ESTROGENS, CONJUGATED (USP); FEMALE; FEMUR; HORSES; HUMANS; HYDROXYPROLINE; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 3; INSULIN-LIKE GROWTH FACTOR I; LUMBAR VERTEBRAE; MEDROXYPROGESTERONE 17-ACETATE; NORPREGNENES; OSTEOCALCIN; OSTEOPOROSIS, POSTMENOPAUSAL;

EID: 0032169242     PISSN: 13697137     EISSN: None     Source Type: Journal    
DOI: 10.3109/13697139809085542     Document Type: Article

References (32)

1. Lindsay R, Hart DM, Aitken JM. Long term prevention of postmenopausal osteoporosis by oestrogen: evidence for an increased bone mass after delayed onset of oestrogen treatment. Lancet 1976;1:1038-41
2. Horsman A, Gallagher JC, Simpson M, et al. Prospective trial of estrogen and calcium in postmenopausal women. Br Med J 1977;274: 789-92
3. Recker RR, Saville PD, Heaney RP. Effect of oestrogen and calcium carbonate on bone loss in postmenopausal women. Ann Intern Med 1977; 87: 649-55
4. Christiansen C, Christiansen MS, McNair O, et al. Prevention of early postmenopausal bone loss: a controlled 2-year study in 315 normal females. Eur J Clin Invest 1980;10:273-9
5. Wren BG, Brown L. Compliance with hormone replacement therapy. Maturitas 1990; 13:17-21
6. Van der Vies J. Pharmacological studies with OD 14. Maturitas 1987;8(Suppl 1):15-24
7. De Visser J, Coert A, Feenstra H, et al. Endocrinological studies with Org OD 14. Arzneim Forsch 1984;34:1010-17
8. Kicovic PM, Cortes-Prieto J, Luisi M, et al. Placebo controlled cross-over study of effects of Org OD 14 in menopausal women. Reproduction 1982;6:81-91
9. Benedek-Jaszmann IJ. Long-term placebo controlled efficacy and safety study of Org OD 14 in climacteric women. Maturitas 1987;8(Suppl 1): 25-33
10. Punnonen R, Luikko P, Cortes-Prieto J. Multicentre study of effects of Org OD 14 on endometrium, vaginal cytology and cervical mucus in post-menopausal and oophorectomized women. Maturitas 1984;5:281-6
11. Genazzani AR, Benedek-Jaszman LJ, Hart DM, et al. Org OD 14 and the endometrium. Maturitas 1991;13:243-51
12. Lindsay R, Hart DM, Kraszewski A. Prospective double blind trial of a synthetic steroid (Org OD 14) for preventing postmenopausal osteoporosis. Br Med J 1980;280:1207-9
13. Geusens P, Dequeker J, Gielen J, et al. Non-linear increase in vertebral density induced by a synthetic steroid (Org OD 14) in women with established osteoporosis. Maturitas 1991;13: 155-62
14. Rymer J, Chapman MG, Fogelman I. Effect of tibolone on postmenopausal bone loss. Osteoporosis Int 1994;4:314-19
15. Bjarnason NH, Bjarnason J, Hassager C, et al. The response in spinal bone mass to tibolone treatment is related to bone turnover in elderly women. Bone 1997;20:151-5
16. Berning B, Kuijk CV, Kuiper JW, et al. Effects of two doses of tibolone on trabecular and cortical bone loss in early postmenopausal women: a two year randomized, placebo controlled study. Bone 1996;19:395-9
17. Lippuner K, Haenggi W, Birkhaeuser MH, et al. Prevention of postmenopausal bone loss using tibolone or conventional peroral or transdermal hormone replacement therapy with 17β-estradiol and dydrogesterone. J Bone Miner Res 1997;12: 806-12
18. Prelevic GM, Bartram C, Wood J, et al. Comparative effects on bone mineral density of tibolone, transdermal oestrogen and oral oestrogen/ progestogen therapy in postmenopausal women (menopausal therapy and bone density). Gynecol Endocrinol 1996;10:413-20
19. Kivirikko KI, Laitenen O, Prockop DJ. Modification of a specific assay for hydroxyproline in urine. Anal Biochem 1967;19:249-55
20. Rymer J, Chapman MG, Fogelman I. The incidence of vaginal bleeding with tibolone treatment. Br J Obstet Gynaecol 1994;101:53-6
21. Watts NB, Harris ST, Genant HK, et al. Intermittent cyclical etidronate treatment of postmenopausal osteoporosis. N Engl J Med 1990; 323:73-9
22. Hillard TC, Whitcroft SJ, Marsh MS, et al. Long term effects of transdermal and oral hormone replacement therapy on postmenopausal bone loss. Osteoporosis Int 1994;4:341-8
23. Naessen T, Persson I, Ljunghall S, et al. Women with climacteric symptoms: a target group for prevention of rapid bone loss and osteoporosis. Osteoporosis Int 1992;2:225-31
24. Ederveen AGH, Kloosterboer HJ. Effect of Org OD 14 and its metabolites on bone mass and bone turnover in ovariectomized rats. Calcif Tissue Int 1994;54:343
25. Johansson AG, Lindh E, Ljunghall S. IGFs: function and clinical importance of growth hormone, insulin-like growth factor I, and bone: a clinical review. J Intern Med 1993;234:553-60
26. Schmid C. IGFs: function and clinical importance 2. The regulation of osteoblast function by hormones and cytokines with special reference to insulin-like growth factors and their binding proteins. J Intern Med 1993;234:535-42
27. Blum WF, Ranke MB. Use of insulin-like growth factor-binding protein 3 for the evaluation of growth disorders. Horm Res 1990;33(Suppl 4): 31-7
28. Cohen P, Fielder PJ, Hasegawa Y, et al. Clinical aspects of insulin-like growth factor binding proteins. Acta Endocrinol 1991;124:74-85
29. Donahue LR, Hunter SJ, Sherblom AP, et al. Age-related changes in serum insulin-like growth factor-binding proteins in women. J Clin Endocrinol Metab 1990;71:575-9
30. Kalu DN, Arjmandi BH, Liu CC, et al. Effects of ovariectomy and estrogen on the serum levels of insulin-like growth factor-I and insulin-like growth factor binding protein-3. Bone Miner 1994;25: 135-48
31. Wüster C, Blum WF, Schlemilch S, et al. Decreased serum levels of insulin-like growth factors and IGF binding protein 3 in osteoporosis. J Intern Med 1993;234:249-55
32. Romagnoli E, Minisola S, Carnevale V, et al. Circulating levels of insulin-like growth factor binding protein 3 and insulin-like growth factor I in perimenopausal women. Osteoporosis Int 1994; 4:305-8